Table 1. Descriptive characteristics of breast cancer patients enrolled in the S0221 trial with assessed toxicity by the availability of DNA at the time of genotyping.
| Variable | Patients with DNA available (n=882) | Patients without DNA available (n=1,180) |
|---|---|---|
| Age, years, mean ± standard deviation | 50.0 ± 10.2 | 50.4 ± 9.9 |
| Self-reported race, N (%) | ||
| European American | 734 (83) | 921 (78) |
| African American | 69 (8) | 149 (13) |
| Asian | 41 (5) | 61 (5) |
| Other | 38 (4) | 49 (4) |
| AC Treatment arm, N (%) | ||
| Arm 1 | 446 (51) | 619 (52) |
| Arm 2 | 436 (49) | 561 (48) |
| CTCAE Grade of hematological toxicity, N (%) | ||
| Grade 0-2 | 592 (67) | 830 (70) |
| Grade 3 | 165 (19) | 175 (15) |
| Grade 4 | 125 (14) | 175 (15) |
| CTCAE Grade of gastrointestinal toxicity, N (%) | ||
| Grade 0-2 | 756 (86) | 1004 (85) |
| Grade 3 | 126 (14) | 172 (15) |
| Grade 4 | 0 (0) | 4 (0) |